Electrolyte Disturbances in Patients with Hyponatremia

George Liamis, Zoi Mitrogianni, Evangelos N. Liberopoulos, Vasilios Tsimihodimos and Moses Elisaf

Abstract

Object Electrolyte abnormalities are frequently observed in patients with hyponatremia. The aim of this study was to determine the incidence of various electrolyte abnormalities encountered in hyponatremic patients admitted to an internal medicine clinic, as well as to investigate the possible pathogenetic mechanisms responsible for these abnormalities.

Patients and Methods We prospectively studied 204 adult patients who either on admission to our clinic or during their hospitalization were found to have hyponatremia.

Results Ninety-two patients (45.5%) had at least one additional electrolyte abnormality. Hypophosphatemia was the most frequent electrolyte disorder observed (35 patients, 17%). Hypokalemia was seen in 32 patients (15.8%), hypomagnesemia in 31 patients (15.2%) and hyperkalemia in 12 patients (5.9%). Moreover, 5 patients (2.5%) had hyperphosphatemia, 4 patients (1.9%) exhibited hypermagnesemia, 3 patients (1.4%) had hypercalcemia, and 6 patients (2.9%) had true hypocalcemia. There were no statistically significant differences regarding the incidence of these electrolyte abnormalities (as a whole) between the main subgroups of hyponatremic patients (diuretic-induced, syndrome of inappropriate antidiuretic hormone, hypovolemia-induced and edematous state-related). However, hypokalemia and hypomagnesemia were more frequently observed in patients with diuretic-induced hyponatremia, while hyperkalemia was more frequently seen in edematous state-related hyponatremia.

Conclusions Additional electrolyte abnormalities are frequently encountered in patients with hyponatremia of any origin admitted to an internal medicine clinic.

Key words: hypokalemia, hypomagnesemia, hypophosphatemia, sodium, diuretics, SIADH

(DOI: 10.2169/internalmedicine.46.6223)

Introduction

Electrolyte abnormalities are commonly seen in patients with a low serum sodium concentration, and their presence can be helpful in establishing the correct diagnosis regarding the underlying cause of hyponatremia (1, 2). There is also some evidence in animals and in man that hypokalemia when present in the hyponatremic state could predispose to the development of demyelination during correction of the hyponatremia (3, 4). Taking into consideration the close link between magnesium, phosphorus and potassium concentrations, the emergence of the concurrent electrolyte disorders in hyponatremic patients may be of paramount importance (5-8). We undertook the present study to determine the incidence of electrolyte abnormalities encountered in hyponatremic patients admitted to our clinic, as well as to illuminate possible pathophysiologic mechanisms responsible for the development of these disorders.

Patients and Methods

During a period of 2.5 years (starting from 5 February 1999), we prospectively studied non selected consecutive adult patients (over years 18 of age), who either on admission to our internal medicine clinic or during their hospitalization were found to have hyponatremia. To be eligible, patients had to have a serum sodium concentration ([Na⁺]) of less than 130 meq/L (reference range 134-145 meq/L) in 2 sequential measurements to exclude potential laboratory errors. Hyperglycemic patients with serum glucose concentrations >180 mg/dL were excluded from the study. On admis-
Diuretic-induced hyponatremia was defined as hyponatremia due to extracellular volume depletion unrelated to diuretics, renal insufficiency unrelated to diuretics, and SIADH.

Prior to any therapeutic intervention, venous blood was obtained for the determination of serum glucose, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, magnesium, phosphorus, total proteins, albumin, triglycerides, osmolality ($P_{osm}$), cortisol and thyroid-stimulating hormone (TSH). Arterial blood was also obtained for blood gas measurements. At the same time, a fresh urine specimen was tested for osmolality ($U_{osm}$), glucose, urea, creatinine, uric acid, sodium, potassium, chloride, calcium, magnesium, phosphorus and proteins. A standard formula was used for the determination of the fractional excretion (FE) of electrolytes. It should be mentioned that FEK$^+$ > 9%, FEPO$^{4-}$ > 20%, FEMg$^{+2}$ > 4% and FECa$^{+2}$ > 3% denote high renal excretion of these parameters (10-14).

Laboratory determinations were done by automated chemical analysis in our laboratory using an Olympus AU 600 analyzer (Olympus Diagnostica, Hamburg, Germany). Specifically, urine and serum samples were analyzed using ion-sensitive electrodes for sodium, potassium, chloride, and calcium, and photometric assays for phosphorus and magnesium. The glutamate dehydrogenase method was used for the determination of urea levels, and a modification of the Jaffe method for creatinine measurement. Serum total protein concentrations were measured by the Biuret method, and serum albumin by the bromocresol green method. The hexokinase and uricase methods were used for the determination of glucose and uric acid levels, respectively. Serum triglycerides were determined by enzymatic colorimetric assay. TSH was measured by microparticle enzyme immunoassay (ABBOTT GmbH Diagnostika, Wiesbaden-Delkenheim, Germany), while serum cortisol levels were estimated by competitive immunoassay (competitive ELISA, Immulite, DPC, Los Angeles, CA, USA).

Arterial pH and PCO$_2$ were determined using a pH blood gas analyzer, and serum bicarbonate was calculated from blood carbon dioxide tension according to the Henderson-Hasselbalch equation with an acidity exponent of 6.10 and a solubility coefficient of 0.0301.

**Statistical analysis**

The results are expressed as mean ± SD. Chi-square test was used for comparisons between groups. P values less than 0.05 were considered to indicate statistical significance.

**Results**

Two hundred and four patients (104 males, 100 females) fulfilled the criteria for inclusion in the study. The causes of hyponatremia are listed in Table 1. Ninety-two patients (45.5%) had at least one electrolyte abnormality. The electrolyte disorders in the study population are shown in Table 2.

Of the 40 patients with diuretic-induced hyponatremia, 12

---

### Table 1. Causes of Hyponatremia

<table>
<thead>
<tr>
<th>Cause</th>
<th>N</th>
<th>Percentage, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIADH*</td>
<td>55</td>
<td>26.9</td>
</tr>
<tr>
<td>Extracellular volume depletion</td>
<td>53</td>
<td>26.0</td>
</tr>
<tr>
<td>Diuretics</td>
<td>40</td>
<td>19.6</td>
</tr>
<tr>
<td>Edematous states**</td>
<td>39</td>
<td>19.1</td>
</tr>
<tr>
<td>Various causes***</td>
<td>17</td>
<td>8.3</td>
</tr>
</tbody>
</table>

*SIADH: syndrome of inappropriate ADH

**Edematous states include hepatic cirrhosis (n = 20), heart failure (n = 16), nephrotic syndrome with marked hypoalbuminemia (n = 3)

**Various causes include primary polydipsia (n = 6), cerebral salt wasting (n = 3), adrenal insufficiency (n = 3), salt-wasting nephropathy (n = 3), and hypothyroidism (n = 2).
Table 2. Electrolyte Abnormalities in Patients with Hyponatremia

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>All patients</th>
<th>SIADH</th>
<th>Hypovolemia</th>
<th>Diuretics</th>
<th>Edematous states</th>
<th>Various causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypokalemia (serum potassium &lt; 3.5 meq/L)</td>
<td>32/204 (15.8%)</td>
<td>3/55 (5.4%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>7/53 (13.2%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>12/40 (30%)</td>
<td>4/39 (10.2%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>6/17 (35.2%)</td>
</tr>
<tr>
<td>Hyperkalemia (serum potassium &gt; 5.5 meq/L)</td>
<td>12/204 (5.9%)</td>
<td>0/55 (0%)</td>
<td>3/53 (5.6%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>0/40 (0%)</td>
<td>8/39 (20.5%)</td>
<td>1/17 (5.9%)</td>
</tr>
<tr>
<td>Hypomagnesemia (serum magnesium &lt; 1.3 meq/L)</td>
<td>31/204 (15.2%)</td>
<td>3/55 (5.4%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>7/53 (13.2%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>12/40 (30.0%)</td>
<td>4/39 (10.2%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>5/17 (29.4%)</td>
</tr>
<tr>
<td>Hypermagnesemia (serum magnesium &gt; 2.1 meq/L)</td>
<td>4/204 (1.9%)</td>
<td>0/55 (0%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>2/53 (3.7%)</td>
<td>0/40 (0%)</td>
<td>0/39 (0%)</td>
<td>2/17 (11.7%)&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hypophosphatemia (serum phosphorus &lt; 2.5 mg/dL)</td>
<td>35/204 (17.0%)</td>
<td>15/55 (27.2%)</td>
<td>8/53 (15.0%)</td>
<td>5/40 (12.5%)</td>
<td>6/39 (15.4%)</td>
<td>1/17 (5.9%)</td>
</tr>
<tr>
<td>Hyperphosphatemia (serum phosphorus &gt; 5 mg/dL)</td>
<td>5/204 (2.5%)</td>
<td>0/55 (0%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>3/53 (5.6%)</td>
<td>0/40 (0%)</td>
<td>1/39 (2.5%)</td>
<td>1/17 (5.9%)</td>
</tr>
<tr>
<td>Hypocalcemia (serum calcium &lt; 8.2 mg/dL)</td>
<td>49/204 (24%)</td>
<td>10/55 (18.2%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>10/53 (18.8%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>1/40 (2.5%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>26/39 (66.6%)</td>
<td>2/17 (11.7%)&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>True hypercalcemia*</td>
<td>6/204</td>
<td>3/55</td>
<td>1/53</td>
<td>0/40</td>
<td>1/39</td>
<td>1/17</td>
</tr>
<tr>
<td>Hypermagnesemia*</td>
<td>(2.9%)</td>
<td>(5.4%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>(1.8%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>(0%)&lt;sup&gt;1&lt;/sup&gt;</td>
<td>(2.5%)</td>
<td>(5.9%)</td>
</tr>
<tr>
<td>Hypermagnesemia (serum calcium &gt; 10.8 mg/dL)</td>
<td>3/204 (1.4%)</td>
<td>1/55 (1.8%)</td>
<td>0/53 (0%)</td>
<td>2/40 (5%)</td>
<td>0/39 (0%)</td>
<td>0/17 (0%)</td>
</tr>
<tr>
<td>Total</td>
<td>92/204 (45.5%)</td>
<td>21/55 (38.8%)</td>
<td>21/53 (39.6%)</td>
<td>22/40 (55.0%)</td>
<td>22/39 (55.4%)</td>
<td>9/17 (52.9%)</td>
</tr>
</tbody>
</table>

*True hypercalcemia denotes hypercalcemia after adjustment for serum albumin concentration

<sup>1</sup>p< 0.05 compared to diuretics
<sup>2</sup>p< 0.05 compared to edematous states
<sup>3</sup>p< 0.05 compared to various causes

(30%) were receiving hydrochlorothiazide (12.5-25 mg/day), 11 (27.5%) the fixed combination of hydrochlorothiazide (50 mg/day) plus amiloride (5 mg/day), 6 (15%) indapamide (2.5 mg/day), and 5 (12.5%) chlorthalidone (25-50 mg/day). The remaining 6 patients (15%) developed hyponatremia while taking various combinations of diuretic agents (hydrochlorothiazide or chlorthalidone plus furosemide or spironolactone). In all patients hypertension was the indication for diuretic administration. It should be noted that in all patients the serum sodium concentration gradually increased after stopping the diuretics. Twenty-two patients (55%) with diuretic-induced hyponatremia had at least one additional electrolyte disturbance. As shown in Table 2, 12 patients (30%) had hypokalemia (range 2.2-3.4 meq/L), which was due to inappropriate kaliuresis (FEK+ > 9%) in all but one patient. Five of the hypokalemic patients also had hypomagnesemia. All together, 12 patients with diuretic-induced hyponatremia (30%) exhibited hypomagnesemia (range 0.6-1.23 meq/L), which was accompanied by inappropriate magnesiumuria (FEMg+ > 4%) in all but one patient. Hypophos-
Phosphatemia (range 1.7-2.4 meq/L) was found in 5 patients (12.5%) and was attended by inappropriate phosphaturia (FEPO₄ > 20%) in all these subjects. Four of the hypophosphatemic patients also had hypokalemia, whereas in 2 of these patients hypomagnesemia was also present.

Of patients with SIADH, 21 (38.8%) had at least one additional electrolyte abnormality. Hypophosphatemia (range 1.6-2.4 meq/L) was the most frequent electrolyte disorder observed in 15 patients (27.2%) and was accompanied by inappropriate phosphaturia in all these patients. Interestingly, 3 hypophosphatemic patients presented also with hypokalemia caused by inappropriate kaliuresis, hypomagnesemia with renal magnesium wasting, and hypocalcemia with inappropriate calciuria. Twenty-one hyponatremic patients (56.4%) due to extracellular volume depletion had one or more additional electrolyte abnormalities. Hypokalemia (range 2.7-3.4 meq/L) was observed in 7 patients (13.2%). Five of the hypokalemic patients had hypomagnesemia and inappropriate kaliuresis, while the remaining 2 patients had a history of gastrointestinal fluid losses. Additionally, all but one hypokalemic patients experienced alkalemia. Hypomagnesemia (range 0.9-1.2 meq/L) was seen in 7 patients (13.2%) with hypovolemic hyponatremia. Five of the hypomagnesemic patients had both inappropriate magnesiuria and at least one additional acid-base or electrolyte disorder: hypokalemia (n=3), hypophosphatemia (n=3), alkalolemia (n=3), and lactic acidosi (n=2). The remaining 2 hypomagnesemic patients presented with diarrhea. Eight patients (15%) with hypovolemic hyponatremia had hypophoshatemia (range 2.1-2.4 meq/L).

Five of the hypophosphatemic patients had inappropriate phosphaturia. Of these, 3 patients also exhibited both hypomagnesemia and alkalolemia, while lactic acidosis was evident in the other 2 patients. The remaining 3 hypophosphatemic patients had an acute diarrhea syndrome. Additionally, hypokalemia (n=3), hyperphosphatemia (n=3) and hypermagnesemia (n=2) was observed in patients with hyponatremia due to extracellular volume depletion and coexistent pre-renal acute renal failure (the mean serum creatinine concentration was 2.8 ± 0.8 mg/dL). Finally, 31 patients (58%) with hypovolemic hyponatremia exhibited alkalolemia (arterial pH > 7.45). Of those, 7 patients (13.2%) had respiratory alkalosis, 4 (7.5%) had metabolic alkalosis, while 20 patients (37.7%) had metabolic alkalosis coexisting with a primary respiratory alkalosis.

Twenty-two hyponatremic patients (56.4%) due to edematous states had at least one additional electrolyte abnormality. It should be noted that all patients with heart failure were receiving an angiotensin-converting enzyme inhibitor plus furosemide (40-80 mg/day), while all patients with hepatic cirrhosis were receiving spironolactone (100-400 mg/day) ± furosemide (40-160 mg/day). As shown in Table 2, hyperkalemia (range 5.8-6.9 meq/L) was found in 8 patients (20.5%) with edematous hyponatremia. Moreover, 6 patients (15.4%) exhibited hypophosphatemia (range 1.8-2.4 meq/L) that was accompanied by inappropriate phosphaturia. Three hypophosphatemic patients had also hypomagnesemia, while alkalolemia (respiratory alkalosis, either alone or in combination with metabolic alkalosis) was observed in all but one patient. Hypokalemia (range 2.5-3.4 meq/L) was observed in 4 patients (10.2%) and was associated by inappropriate kaliuresis in all of these. Two hypokalemic patients had also hypomagnesemia. In 4 patients (10.2%) with edematous hyponatremia, low serum magnesium levels were found that were accompanied by inappropriate magnesiuria in all but one patient. All patients with hypokalemia and hypomagnesemia also had alkalalemia. Furthermore, hyperphosphatemia was seen in one patient with acute renal failure.

There were no statistically significant differences regarding the incidence of the additional electrolyte abnormalities (as a whole) among the subgroups of hyponatremic patients. However, hypokalemia and hypomagnesemia were more frequently observed in patients with diuretic-induced hyponatremia, while hyperkalemia in edematous hyponatremia (as compared with all the other subgroups). Additionally, as far as the incidence of hypophosphatemia is concerned there were no statistically significant differences between the subgroups of hyponatremic patients (Table 2). It should be noted that in all subgroups of patients, the serum sodium concentration was not correlated with the serum levels of all the other electrolytes studied (data not shown).

**Discussion**

Additional electrolyte abnormalities were observed in a considerable percentage of our hyponatremic patients independent of the cause of hyponatremia. Taking into consideration the absence of statistically significant correlations between serum sodium and other electrolyte levels, these disturbances should be ascribed mainly to the underlying cause of hyponatremia rather than to hyponatremia per se.

More than half of patients with diuretic-induced hyponatremia exhibited at least one additional electrolyte abnormality. Specifically, hypokalemia, hypomagnesemia, and hypophosphatemia were detected in a substantial fraction of these patients. Potassium, magnesium and phosphorus depletion can be induced by diuretic therapy as a result of urinary losses (15-17). Furthermore, experimental and clinical observations have demonstrated a close link among potassium, magnesium, and phosphorus concentrations (5-8). Indeed, potassium depletion is associated with increased urinary excretion of magnesium, calcium, and phosphorus, while magnesium depletion causes kaliuresis and potassium depletion (6, 7, 18). Moreover, magnesium depletion leads to renal phosphate wasting and phosphate depletion, although hypophosphatemia only rarely develops (19).

Hypophosphatemia was the most frequent electrolyte disorder in patients with hyponatremia due to SIADH. However, this parameter lacks satisfactory specificity in diagnosing SIADH given that hypophosphatemia was not infrequently observed in the other subgroups of our hyponatremic patients. Hypophosphatemia in SIADH patients can be
attributed to volume expansion, since experimental studies clearly showed that volume expansion evoked an inhibition of phosphate uptake by the renal proximal tubules (20). In fact, in our study all hypophosphatemic patients due to SIADH exhibited inappropriate phosphaturia. Apart from hypophosphatemia, other electrolyte disorders have frequently been described in patients with SIADH. Interestingly, 3 of our SIADH subjects presented with a constellation of metabolic abnormalities and specifically hypophosphatemia, hypokalemia with inappropriate kaliuresis, hypomagnesemia caused by renal magnesium wasting, as well as hypocalcemia with inappropriate calciuria. Volume expansion and coexistent hypophosphatemia that both decrease passive magnesium reabsorption might explain the hypomagnesemia observed. Moreover, the potassium wasting observed should be ascribed to the coexistent hypomagnesemia or less possibly to the hypotonicity-induced elevation of aldosterone secretion, which is observed when plasma osmolality falls below 240 mosm/kg and can counterbalance the influence of the extracellular fluid expansion on renin-aldosterone axis (21, 22). Moreover, hypocalcemia should be attributed to the coexistent hypophosphatemia, which is known to impair the release of parathyroid hormone (PTH) and induce skeletal resistance to its actions (23, 24). Hypophosphatemia-related calciuria could also have contributed to the observed hypocalcemia taking into consideration that low serum phosphorus levels stimulate the production of 1,25-dihydroxy-vitamin D, which leads to an augmented intestinal calcium absorption and hypercalcuria (25, 26). Consequently, in few SIADH patients multiple interrelated electrolyte abnormalities may be found, which could, at least partially, be ascribed to the extracellular volume expansion.

In hypovolemic hyponatremia, 15% of patients exhibited hypokalemia that may be attributed to hypomagnesemia related kaliuria or to gastrointestinal potassium loss, while the coexistent alkalalemia may also have played a contributory role. Moreover, renal and extrarenal magnesium loss were the main pathogenetic mechanisms regarding the emergence of hypomagnesemia in these patients, whereas an increased transcellular magnesium shift from the extracellular to intracellular department may have contributed to the decreased serum magnesium levels in patients with alkalalemia. Finally, metabolic acidosis and phosphate depletion observed in some hypomagnesemic patients could have been responsible for the inappropriate magnesiuria, which has been shown to arise from reduced magnesium reabsorption in the loop of Henle as well as in the distal tubule (27, 28). Inappropriate urinary phosphate loss was the leading cause of hypophosphatemia observed in our hyponatremic patients due to extracellular volume depletion. This inappropriate phosphaturia was attributed to hypomagnesemia, or acidemia. Even though hypophosphatemia could be the cause of inappropriate magnesiuria and hypomagnesemia, in some cases, it might also be the result of hypomagnesemia (29, 30). Acute metabolic acidosis also causes loss of phosphate in the urine and enhances cellular release of the phosphate anions (31). Additionally, intracellular shift of phosphate may have played a prominent role in the development of hypophosphatemia in patients with alkalosis.

Hyperkalemia was observed in a considerable percentage of patients with edematous hyponatremia and can be mainly ascribed to the administration of converting enzyme inhibitors or potassium-sparing diuretics (mainly spironolactone) in the setting of effective circulating volume depletion. Furthermore, low potassium or magnesium dietary intake in mальnourished patients with severe heart or hepatic failure as well as the alkalalemia-related tranacellular shift of these ions from the extracellular to the intracellular department significantly contributes to the decreased serum potassium or magnesium levels occasionally encountered in these patients. However, the leading cause of both hypokalemia and hypomagnesemia in patients with edematous hyponatremia was the administration of furosemide (32). Moreover, hypophosphatemia was mainly due to inappropriate phosphaturia, which can be attributed to hypomagnesemia as well as to a phosphaturic effect of diuretics. Intracellular shift of phosphate in patients with alkalosis (33), as well as a decreased intake of phosphorus-rich food may also have played a contributory role in the development of hypophosphatemia.

In conclusion, additional electrolyte abnormalities are frequently seen in hyponatremic patients, independently of hyponatremia cause, due to various interrelated pathogenetic mechanisms. The most common of these disorders include hypophosphatemia, hypokalemia and hypomagnesemia.

References


9. Bartter FC, Schwartz WB. The syndrome of inappropriate secre-